



A




ID	Diagnosis	Grade	Tumor size (mm)	Comments	Stage Grouping	LN positive	Primary Site	Histology Description
OPTR 3793	Adenocarcinoma	Grade II	48		2B - IIB	5/18	Pancreas	Invasive adenocarcinoma
OPTR 7021	Infiltrating duct carcinoma	N/S	15	Liver met	2A	0/22	Pancreas	Ductal carcinoma
OPTR 3560	Adenocarcinoma	N/S	46		2A - IIA	NA	Pancreas	Adenocarcinoma
OPTR 3578	Adenocarcinoma	Grade II	37		2B - IIB	1/20	Pancreas	Adenocarcinoma

B



C



D





Figure S8. Drug profiling on PDAC patient derived tumor organoids (PDTOs). A. PDAC patient-derived tumor organoids; brightfield images, scale 1000μm; disease characterization, diagnosis, histological assessment. B. Heatmap of drug profiling results using the CTD² network informer set (CNIS) drug library was performed on 4 KRAS mutant PDAC PDTOs; potency shown in AUC; x indicates no data; drug target group curation of top 50 agents ranked by both AUC and IC50 values (right). C. Representative brightfield images of the normal pancreas organoid (NPO) and 5 KRAS mutant PDAC PDTOs used in preclinical organoid screening platform; scale 1000 μm. D. Preclinical organoid screening platform with FDA-approved therapeutics for PDAC and novel agents including TFIIH/XPB/CDK transcriptional kinase inhibitors; scatter plot of calculated IC50s from fitted dose response curves on 5 KRAS mutant PDAC PDTOs (left); scatter plot of potency fold change vs. normal pancreas organoid (NPO) IC50s from fitted dose response curves (right).